3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
11
Obesity
4
Sarcopenia
3
Polycystic Ovary Syndrome
3
Neoplasms
3
Melanoma
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Malnutrition
2
Lymphoma, Follicular
2
Colorectal Neoplasms
2
Breast Carcinoma In Situ
2
Wound Infection
1
Weight Loss
1
Urinary Bladder Neoplasms
1
Surgical Wound Infection
1
Stomach Neoplasms
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Psoriasis
1
Precancerous Conditions
1
Postoperative Complications
1
Polyps
1
Phagocyte Bactericidal Dysfunction
1
Pain
1
Paget's Disease, Mammary
1
Overweight
1
Osteoarthritis
1
Olfaction Disorders
1
Non-alcoholic Fatty Liver Disease
1
Interventions
Adalimumab
13
Methotrexate
11
Etanercept
10
Rituximab
5
Abatacept
5
tocilizumab
4
olokizumab
4
tofacitinib
3
golimumab
3
Infliximab
3
Tumor Necrosis Factor Inhibitors
2
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
Certolizumab Pegol
2
Antirheumatic Agents
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Arthritis, Rheumatoid
×
Docosahexaenoic Acids
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts